Cancer Clinical Trial
— PARCOfficial title:
A Phase I/II Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100) in Relapsed/Refractory Cancers of Children and Young Adults
Verified date | September 2022 |
Source | University of Birmingham |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
PARC is an international phase I/II trial evaluating the safety and activity of pegylated recombinant human arginase (BCT-100) in children and young people with relapsed/refractory leukaemia, neuroblastoma, sarcoma and high grade gliomas (brain cancers). Currently the outcomes for these patients are poor and the therapeutic options are limited with a significant toxicity burden. Therefore new treatments which work in different ways to standard chemotherapy are urgently needed. Research has shown that arginine (a nutrient) is important in the survival of cancer cells. BCT-100 is a drug which can deplete arginine levels and starve cancer cells - a completely new approach. BCT-100 has been tested in adults and shown to be active with almost no side-effects. This trial will test whether this dose of BCT-100 is also safe and active in children with relapsed/refractory leukaemia, neuroblastoma, sarcoma and high grade glioma. The trial will also study how BCT-100 is broken down in the body and look for new biological markers of treatment response. Up to 64 children with relapsed cancers will be recruited over 2 years.
Status | Completed |
Enrollment | 49 |
Est. completion date | July 22, 2022 |
Est. primary completion date | July 22, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 1 Year to 25 Years |
Eligibility | Inclusion Criteria: - Aged 1- <25 years old at the time of study registration - Histologically confirmed disease in one of the following four groups: - Group 1 - Acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML) - Group 2 - Neuroblastoma Group 3 - Sarcoma - Group 4 - High grade glioma (as defined by 2016 WHO CNS classification) - Radiological or laboratory evidence of disease progression (during or after completion of first line treatment) or any subsequent recurrence (biopsy at relapse is not mandated). - Measurable bone marrow disease (group 1) or at least one evaluable radiological site of disease (group 2, 3 and 4). - Adequate liver function defined as a total bilirubin =1.5x the upper limit of normal for age and ALT = 3x the upper limit of normal for age - Documented negative pregnancy test for female patients of childbearing potential within 7 days of trial entry - Sexually active patients must agree to use adequate and appropriate contraception while on study drug and for 12 months following treatment discontinuation - Written informed consent given by patient and/or parents/legal representative Exclusion Criteria: - Previous treatment with another therapeutic arginine depleting drug (bacterial or human) or arginase inhibitor - Presence of any = CTCAE grade 3 clinically significant treatment-related toxicity from prior therapies - Pregnant or lactating female - Evidence of uncontrolled infection |
Country | Name | City | State |
---|---|---|---|
Australia | Women's & Children's Hospital | Adelaide | |
Australia | Queensland Children's Hospital | Brisbane | |
Australia | Royal Children's Hospital Melbourne | Melbourne | |
Australia | Perth Children's Hospital | Perth | |
Australia | Children's Hospital Westmead | Sydney | |
Australia | Sydney Children's Hospital | Sydney | |
Netherlands | Princes Maxima Centrum | Utrecht | |
United Kingdom | Birmingham Children's Hospital | Birmingham | |
United Kingdom | Bristol Royal Hospital for Children | Bristol | |
United Kingdom | Addenbrookes Hospital | Cambridge | |
United Kingdom | Royal Hospital for Children | Glasgow | |
United Kingdom | Leeds Children's Hospital | Leeds | |
United Kingdom | Royal Manchester Children's Hospital | Manchester | |
United Kingdom | Royal Marsden Hospital | Sutton |
Lead Sponsor | Collaborator |
---|---|
University of Birmingham |
Australia, Netherlands, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Phase I: to establish the recommended phase II dose (RP2D) of BCT-100 in children and young adults as assessed by dose limiting toxicity (DLT) and complete arginine depletion | Safety profile as measured by the occurrence/non-occurrence of DLT within 28 days of treatment with BCT-100.
o Optimal dose as measured by the complete depletion of arginine. This is defined as AAD <8µM arginine in the blood after 3 doses of BCT-100. |
28 days | |
Primary | Phase II: to determine the activity of single agent BCT-100 against relapsed/refractory leukaemia, neuroblastoma, sarcoma and high grade glioma in children and young adults as measured by disease response after 8 weeks. | Disease response (Complete Response (CR) or Partial Response (PR)) after 8 weeks of treatment with BCT-100 | After 8 weeks | |
Secondary | The incidence and severity of Adverse Events (AEs) as Assessed by CTCAE v4 | Incidence and severity of Adverse Events (AEs) defined by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v4 | 28 days after treatment completion | |
Secondary | Disease response - Leukaemia | Disease response ( CR / PR) according to Cheson criteria | Within 1 year | |
Secondary | Disease response - Sarcoma | Disease response ( CR / PR) according to RECIST criteria | Within 1 year | |
Secondary | Disease response - High Grade Glioma | Disease response ( CR / PR) according to RANO criteria | Within 1 year | |
Secondary | Disease response - Neuroblastoma | Disease response ( CR / PR) according to INCR criteria | Within 1 year | |
Secondary | Progression free survival (PFS) | Up to three years after registration | ||
Secondary | Overall survival (OS). | Up to three years after registration | ||
Secondary | Maximum Plasma Concentration [Cmax], of BCT-100 in the paediatric population. | Up to 24 weeks | ||
Secondary | Time to maximum Plasma Concentration [Tmax], of BCT-100 in the paediatric population. | Up to 24 weeks | ||
Secondary | Minimum Plasma Concentration [Cmin], of BCT-100 in the paediatric population. | Up to 24 weeks | ||
Secondary | Area Under the Curve [AUC], of BCT-100 in the paediatric population. | Up to 24 weeks | ||
Secondary | Duration of adequate arginine depletion in blood. | BCT-100 concentration in blood | Up to 24 weeks | |
Secondary | Duration of adequate arginine depletion in bone marrow . | BCT-100 concentration in bone marrow | Up to 24 weeks | |
Secondary | Duration of adequate arginine depletion in cerebrospinal fluid. | BCT-100 concentration in cerebrospinal fluid | Up to 24 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|